Ethics & Informed Consent: Randomised Controlled Trial (RCT) (China)
A detailed academic review of the ethical submission protocol, informed consent prerequisites, and reporting standards for conducting a Randomised Controlled Trial (RCT) within the regulatory framework of China.
1. Ethical Principles & Legislative Framework
In research involving human participants, securing ethical clearance is a critical first step. For a Randomised Controlled Trial (RCT) being conducted in China, study designs must align with the primary regulatory legislation: Measures for Ethical Review of Life Science and Medical Research Involving Humans. This statutory framework ensures participant welfare, confidentiality, and voluntary involvement are protected.
National Ethics Board Clearance Pathway
In China, ethics reviews are governed by National Health Commission measures. Data exports or genetic data sharing must comply with HGRAC (Human Genetic Resources Administration) reviews and PIPL rules.
Administrative review and formal approval are managed by a local or regional Institutional Ethics Committee. Researchers must secure full approval or a formal exemption certificate from this board before recruiting any participants or commencing data collection.
2. Study Design Elements & Reporting Integrity
For a Randomised Controlled Trial (RCT), the review board places significant focus on methodological transparency. The application must outline the research rationale, recruitment protocols, inclusion and exclusion criteria, and data protection measures.
Study Classification: High Risk (Interventional)
RCTs are interventional, requiring robust safety oversight, clear drug/device allocation concealment protocols, and detailed descriptions of emergency unblinding procedures.
To guarantee academic integrity and reproducibility, the study report and subsequent publications should follow the internationally recognised reporting standard: CONSORT statement.
Special Directive: Interventional Study Protocols
Because this study design is classified as interventional, the Institutional Ethics Committee requires pre-registration of the trial on a public clinical registry (e.g. ClinicalTrials.gov or a regional WHO-compliant database) before patient enrolment begins. A detailed adverse event reporting protocol must also be submitted.
3. Informed Consent & Information Sheet Guidelines
A robust participant information sheet and informed consent form are critical parts of the ethical application. Ensure your documentation incorporates the following components:
Design-Specific Consent Focus Areas
Explicit random assignment details, placebo justification guidelines, active side effect monitoring, and safety thresholds.
- Plain Language Explanations: Avoid complex medical or technical terminology. Ensure readability matches the general population.
- Voluntary Participation: Explicitly state that participation is entirely voluntary and that individuals can withdraw at any time without negative consequences.
- Confidentiality & Data Controls: Explain how participant data will be anonymised or pseudonymised, who will have access to it, and how long it will be securely retained under Personal Information Protection Law (PIPL).
- Risk/Benefit Disclosure: Clearly list any potential risks, discomforts, or direct benefits associated with participation in the study.
- Ethics Board Contact Information: Provide the contact details of the reviewing Institutional Ethics Committee so participants can reach out if they have questions or concerns.
Research Ethics, Clinical Trials & Institutional Governance
Designing a study protocol for this Randomised Controlled Trial (RCT) in China requires addressing complex ethical considerations in research for human participants. When recruiting participants in China, investigators must implement strict safeguards for vulnerable populations research ethics. Prior to any intervention, subjects must sign a comprehensive research consent form outlining potential side effects and protocols. Depending on the protocol, some secondary screening phases may satisfy irb exempt research criteria to streamline approvals. Any wet-lab procedures must declare their containment ratings, keeping facilities at biosafety level 1 2 3 4 based on pathogen risk. Ethical oversight committees in China audit the study's consent registry periodically to verify compliance with national legal statutes.
4. Regulatory Checklist Table
To streamline your ethical review submission, use the structured alignment checklist below:
| Requirement | Institutional Ethics Committee Standard | CONSORT statement Standard |
|---|---|---|
| Consent Form | Signed and dated prior to study activity. Focus: Explicit random assignment details. | Fully documented recruitment and consent paths. |
| Risk Management | Comprehensive risk mitigation plan. Mandates establishing an independent Data Safety Monitoring Board (DSMB) and registering the trial on a public registry (e.g., ClinicalTrials.gov). | Adverse events reporting strategy. |
| Data Retention | Compliance with local data protection rules (Personal Information Protection Law (PIPL)). | Provision of open-data options where possible. |
5. Academic & Research Infrastructure Matrix (China)
The following authenticated registry lists top scientific organizations, clinical laboratories, and research hospitals in China mapped via the Research Organization Registry (ROR) standards-compliance framework.
| Organization Name | Sector Type | Registry Identification |
|---|---|---|
| China Mobile (China) | company | ROR IDWikidata/Wiki |
| China Post (China) | company | ROR IDWikidata/Wiki |
| China Telecom (China) | company | ROR IDWikidata/Wiki |
| China Minmetals (China) | company | ROR IDWikidata/Wiki |
| China Resources (China) | company | ROR IDWikidata/Wiki |
| China Datang Corporation (China) | company | ROR IDWikidata/Wiki |
| China State Shipbuilding (China) | company | ROR IDWikidata/Wiki |
| China XD Group (China) | company | ROR IDWikidata/Wiki |
| China Shenhua Energy (China) | company | ROR IDWikidata/Wiki |
| China Huadian Corporation (China) | company | ROR IDWikidata/Wiki |
| China Design Group (China) | company | ROR ID |
| China Huarong Energy (China) | company | ROR ID |
| China Electronics Corporation (China) | company | ROR IDWikidata/Wiki |
| China Ocean Shipping (China) | company | ROR IDWikidata/Wiki |
| China Guodian Corporation (China) | company | ROR IDWikidata/Wiki |
6. Frequently Asked Questions
How long does the review process normally take?
Review timelines depend on the volume of applications and whether your proposal qualifies for expedited review. On average, a standard review by an ethics board in China takes between 4 to 8 weeks.
Can we use digital signatures for informed consent?
Yes, digital consent forms are increasingly accepted, provided the platform used is secure, authenticates the identity of the signer, and complies with local regulations such as the eIDAS or ESIGN Act, depending on country-specific rules.
Regulatory Context
Verified Funding Bodies
Funder registries and DOI configurations verified for compliance in China via Crossref.
- China Steel CorporationID: 501100013923 | Location: Taiwan
- Chinati FoundationID: 100025814 | Location: United States
- ChinaSona FoundationID: 100028428 | Location: United States
- Agriculture Research System of ChinaID: 501100010203 | Location: China
- National Key Research and Development Program of ChinaID: 501100012166 | Location: China
- China Medical BoardID: 100001547 | Location: United States
- China Tobacco Guangxi IndustrialID: 501100002659 | Location: China
- West China Hospital, Sichuan UniversityID: 501100013365 | Location: China
- North China Power EngineeringID: 501100003994 | Location: China
- Postdoctoral Research Foundation of ChinaID: 501100010031 | Location: China
Pre-Submission Warning
Do not recruit participants or initiate study procedures before receiving official written approval from your reviewing board. Ethical approvals cannot be granted retrospectively under Measures for Ethical Review of Life Science and Medical Research Involving Humans.
